Dupixent takes pharma DTC top spot in September
WEB1 day ago · Skyrizi has been dominating the 2024 DTC ranking list alongside Rinvoq, which came in third in September, though spending on the med’s commercials dropped by a significant $6.2 million. Dupixent ...
BMS' schizophrenia gem Cobenfy was rescued from the scrapheap
WEB1 day ago · Bristol Myers Squibb Karuna Therapeutics PureTech Health schizophrenia. Off the scrapheap of discarded drugs and on its way to becoming the most highly anticipated approval of 2024, Bristol Myers ...
Fierce 50 of 2024 | Fierce Pharma
WEBI’m honored to introduce the second edition of the Fierce 50, where we once again spotlight the innovators and leaders driving the future of healthcare, pharma and biotech. This year’s ...
In long-acting HIV PrEP access showdown with Gilead, GSK moves …
WEB1 day ago · GSK’s ViiV Healthcare unit is countering rival HIV drugmaker Gilead’s recent global access moves with its own pledge to make at least 2 million doses of its long-acting pre-exposure ...
Big Pharma Companies Ranked by Revenue 2022 - Fierce Pharma
WEBBy Kevin Dunleavy Apr 18, 2023 12:00am. Johnson & Johnson Pfizer revenue growth Roche. Pfizer made biopharma industry history in 2022, becoming the first company to ring up $100 billion in revenue ...
AstraZeneca's vision for the future of respiratory care
WEB1 day ago · Sponsored By AstraZeneca Oct 7, 2024 8:00am. Pharma. Respiratory medicine is one frontier of the global healthcare landscape which has undergone significant transformations in recent years ...
Fierce Pharma Asia—Deal spree by AstraZeneca, J&J, Roche, …
WEBJan 5, 2024 · The last few days of 2023 and the beginning of 2024 featured a flurry of dealmaking by the likes of AstraZeneca, Johnson & Johnson, Roche and Boehringer Ingelheim with Asian companies.
The top 20 pharma companies by 2021 revenue
WEBOf the world’s top 20 pharmas ranked by 2021 revenues, 12 had at least 10% growth, including five that saw their sales boom at least 40%. No company pulled in more revenue from COVID products ...
AstraZeneca plans independent drug supply chains for US and …
WEBMar 27, 2024 · As geopolitical tensions threaten to disrupt pharmaceutical supply chains, AstraZeneca is making plans to manufacture drugs for the U.S. and China markets independently from one another. “We ...
2021 drug approvals: In a year dominated by COVID, biopharma …
WEBEach year, many scientists and other experts working in the biopharma industry see years of their work culminate in FDA approvals. With the COVID-19 crisis stretching into its third year, the 2021 ...